Abstract
Recent research progress toward new technologies for managing diabetes mellitus prompts consideration of related public policy. As guides to this technological development: 1) the potential societal value of specific advances should be estimated; and 2) scientific, commercial, and public concerns should be reflected. In evaluating the new technologies: 1) the cost-effectiveness format for comparing net monetary effects to net health effects seems suitable; 2) the long lead time required to assess many diabetic effects suggests that evaluation of the technologies commence even while their modification continues; 3) a premium is placed on identifying observable short-term effects linked to long-term outcomes; and 4) the placebo effect should be scrutinized. Apace with evaluation of technologies should come evalution and modification of public polices for dealing with them.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
